Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in...

|About: MannKind Corporation (MNKD)|By:, SA News Editor

Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy.